QuantiFERON-TB performance enhanced by novel Mycobacterium tuberculosis-specific antigens.

Abstract

One of the most significant developments in the diagnosis of tuberculosis (TB) infection has been the introduction of whole-blood based interferon-γ release assays (IGRAs) [1–3]. IGRAs, commercially available as QuantiFERON-TB Gold In-Tube test (QFT) (QIAGEN, Germantown, MD, USA) and T-SPOT.TB (Oxford Immunotec Ltd, Abingdon, UK), are based on the detection of a T-cell immune response towards RD1 antigens (ESAT-6 and CFP-10), with the addition of the TB7.7 antigen for the QFT only [1]. IGRAs are endowed with great specificity, as the antigens used are almost exclusively expressed by the Mycobacterium tuberculosis (MTB) complex, but not Mycobacterium bovis bacille Calmette–Guerin (BCG) [1–3]. However, the diagnostic sensitivity of IGRAs can be improved (75–85% in HIV-negative active TB patients) especially in countries with a high TB burden [3].

DOI: 10.1183/13993003.01015-2015

1 Figure or Table

Cite this paper

@article{Losi2016QuantiFERONTBPE, title={QuantiFERON-TB performance enhanced by novel Mycobacterium tuberculosis-specific antigens.}, author={Monica Losi and Ashley J. Knights and Francesca V Mariani and Alfonso Maria Altieri and Gregorino Paone and Andre Gareth Loxton and Novel N Chegou and John Kenneth and Mario Giuseppe Alma and Vittorio Colizzi and Gerhard Walzl and Cesare Saltini and Jeff Boyle and Massimo Amicosante}, journal={The European respiratory journal}, year={2016}, volume={47 2}, pages={660-4} }